# OnCo record rejuv-tx-gene-modified-follow-up (technology). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/technologies/rejuv-tx-gene-modified-follow-up/>
  a schema:MedicalTherapy ;
  onco:kind "technology" ;
  schema:identifier "rejuv-tx-gene-modified-follow-up" ;
  schema:name "Long-term follow-up for gene-modified cell products: fifteen years, and why"@en ;
  schema:alternateName "LTFU gene therapy"@en, "15-year follow-up CAR-T"@en, "gene therapy long term follow-up guidance"@en ;
  schema:description "If you were given a treatment in which your own cells were genetically modified, you are expected to be followed up for fifteen years. Not because something is known to go wrong, but because the gene is inserted permanently and the only honest way to find out what happens over a lifetime is to look."@en ;
  schema:url <https://onco.cc/technologies/rejuv-tx-gene-modified-follow-up/> ;
  schema:dateModified "2026-10-02"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Gene_therapy> ;
  schema:citation <https://www.fda.gov/regulatory-information/search-fda-guidance-documents/long-term-follow-after-administration-human-gene-therapy-products>, <https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/fda-requires-boxed-warning-t-cell-malignancies-following-treatment-bcma-directed-or-cd19-directed>, <https://doi.org/10.1056/NEJMp2400209>, <https://www.factglobal.org/standards/> ;
  onco:status "standard-of-care" ;
  onco:tag "rejuvenation", "survivorship", "transplant", "evidence:strong", "cell-therapy", "regulation" ;
  onco:related <https://onco.cc/technologies/rejuv-tx-secondary-t-cell-malignancy/>, <https://onco.cc/technologies/rejuv-tx-long-term-follow-up-frameworks/>, <https://onco.cc/technologies/rejuv-tx-what-to-ask-for/> ;
  onco:sections <https://onco.cc/fronts/rejuvenation/>, <https://onco.cc/fronts/supportive-care/> ;
  onco:technologies <https://onco.cc/technologies/car-t/> ;
  onco:terms <https://onco.cc/terms/secondary-malignancy/>, <https://onco.cc/terms/late-effects/> ;
  onco:bottlenecks <https://onco.cc/bottlenecks/b-survivorship/> .